289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (23rd October 2018)

Record Type:: Journal Article
Title:: 289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. (23rd October 2018)
Main Title:: 289PDLucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial
Authors:: Hui, R
Pearson, A
Cortes Castan, J
Campbell, C
Poirot, C
Azim, H A
Fumagalli, D
Lambertini, M
Daly, F
Arahmani, A
Perez-Garcia, J
Aftimos, P G
Bedard, P
Xuereb, L
Loibl, S
Loi, S
Pierrat, M-J
Turner, N C
André, F
Curigliano, G
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 8
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 8
Issue Display:: Volume 29, Issue 8 (2018)
Year:: 2018
Volume:: 29
Issue:: 8
Issue Sort Value:: 2018-0029-0008-0000
Page Start:
Page End:
Publication Date:: 2018-10-23
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy272.281 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12255.xml